Acromegaly
Welcome,         Profile    Billing    Logout  
 24 Companies   9 Products   9 Products   6 Mechanisms of Action   50 Trials   3648 News 


«12...1213141516171819202122...5960»
  • ||||||||||  Acromegaly (Twitter) -  Nov 22, 2022   
  • ||||||||||  Somavert (pegvisomant) / Pfizer
    Journal:  Pegvisomant in the treatment of acromegaly. (Pubmed Central) -  Nov 21, 2022   
    In addition, pituitary tumor growth progression has been reported in several cases. In this review article, we present long-term data on pegvisomant treatment and discuss its associated risks and benefits.
  • ||||||||||  Review, Journal:  The state of Sergipe contribution to GH research: from Souza Leite to Itabaianinha syndrome. (Pubmed Central) -  Nov 18, 2022   
    This research, which was carried out over almost 30 years, was performed in partnership with Roberto Salvatori from Johns Hopkins University and in collaboration with other researchers around the world. This review article tells the story of Souza Leite, some milestones in the history of GH, and summarizes the description of Itabaianinha syndrome.
  • ||||||||||  Somavert (pegvisomant) / Pfizer, Signifor (pasireotide) / Recordati
    Review, Journal:  Approach of Acromegaly during Pregnancy. (Pubmed Central) -  Nov 16, 2022   
    Most data are on octreotide > lanreotide, followed by DAs and pegvisomant, and there are none on pasireotide...One study showed a 2-year median between hypophysectomy and pregnancy. Close surveillance of disease burden is required, particularly, concerning CMF; a personalized approach is useful; the level of statistical evidence is expected to expand due to recent progress in MNA and ART.
  • ||||||||||  Journal:  The Integrated Stress Response Is Tumorigenic and Constitutes a Therapeutic Liability in Somatotroph Adenomas. (Pubmed Central) -  Nov 16, 2022   
    In in vitro experiments, the knockdown of EIF2β changed the phenotype of somatotroph adenomas, including cell proliferation, migration, and the secretion ability of growth hormone/insulin-like growth factor-1. In this study, we demonstrate that the ISR is pivotal in somatotroph adenomas and provide a rationale for implementing ISR-based regimens in future treatment strategies.
  • ||||||||||  Journal:  Acromegaly features in performing Marionette. (Pubmed Central) -  Nov 15, 2022   
    Both uncontrolled disease and hypogonadism contribute to TBS deterioration in acromegaly. No abstract available
  • ||||||||||  cabergoline / Generic mfg.
    Pituitary Macroadenomas in Childhood and Adolescence. Clinical Analysis of 7 Cases (Rome, Italy) -  Nov 13, 2022 - Abstract #ESPE2022ESPE_1528;    
    It is important to perform genetic studies in patients with macroadenomas appearing under the age of 30 years as genetic and syndromic associations are more frequently seen. Once the genetic alteration has been identified, a better follow-up and treatment can be done together with a family study.
  • ||||||||||  Signifor (pasireotide) / Recordati
    Somatostin analogs in a 15 year old boy with gigantism (Rome, Italy) -  Nov 13, 2022 - Abstract #ESPE2022ESPE_1501;    
    As pituitary gigantism is rare and disease control is difficult to achieve, medical treatment with somatostatin analogues is a useful resource. In this case it showed adequate safety and a moderately good response, especially in regard to his visual fields, avoiding the need for second surgery or radiotherapy for the time being.
  • ||||||||||  Usefulness of Next Generation Sequencing in the Molecular Diagnosis of McCune-Albright Syndrome in Peripheral Blood (Rome, Italy) -  Nov 13, 2022 - Abstract #ESPE2022ESPE_1475;    
    In this case it showed adequate safety and a moderately good response, especially in regard to his visual fields, avoiding the need for second surgery or radiotherapy for the time being. NGS represents a more sensitive tool for identifying GNAS mutations in peripheral blood, even with low abundance, in patients with MAS, with the advantage of analyzing multiple positions.
  • ||||||||||  Journal:  A Novel Missense PRKAR1A Variant Causes Carney Complex. (Pubmed Central) -  Nov 8, 2022   
    This study broadens our understanding of the genetic spectrum of CNC. We suggest that PRKAR1A genetic testing and counseling be recommended for patients with CNC and their families.
  • ||||||||||  Journal:  The effect of Mindfulness therapy in acromegaly, a pilot study. (Pubmed Central) -  Nov 8, 2022   
    We suggest that PRKAR1A genetic testing and counseling be recommended for patients with CNC and their families. We have demonstrated for the first time the value of a mindfulness program in patients with acromegaly, analysing possible effects and advantages, and clarifying the usefulness of a specific protocol for the disease.
  • ||||||||||  Somavert (pegvisomant) / Pfizer
    Enrollment closed, Trial completion date, Trial primary completion date:  PegvisOMant and the Immune SystEm (PROMISE) (clinicaltrials.gov) -  Nov 8, 2022   
    P=N/A,  N=30, Active, not recruiting, 
    We have demonstrated for the first time the value of a mindfulness program in patients with acromegaly, analysing possible effects and advantages, and clarifying the usefulness of a specific protocol for the disease. Recruiting --> Active, not recruiting | Trial completion date: Jun 2022 --> Mar 2023 | Trial primary completion date: Mar 2022 --> Dec 2022
  • ||||||||||  Biomarker, Journal:  Delayed postoperative hyponatremia in patients with acromegaly: incidence and predictive factors. (Pubmed Central) -  Nov 4, 2022   
    Recruiting --> Active, not recruiting | Trial completion date: Jun 2022 --> Mar 2023 | Trial primary completion date: Mar 2022 --> Dec 2022 The findings suggested that lower preoperative weight and a postoperative transient gain in body weight are associated with an increased risk of DPH in acromegaly patients undergoing transsphenoidal surgery.
  • ||||||||||  Review, Journal:  Acromegaly: pathogenesis, diagnosis, and management. (Pubmed Central) -  Nov 2, 2022   
    A multimodal approach with surgery, medical therapy, and (more rarely) radiation therapy is required to achieve these goals. In this Review, we examine the epidemiology, pathogenesis, diagnosis, complications, and treatment of acromegaly, with an emphasis on the importance of tailoring management strategies to each patient to optimise outcomes.
  • ||||||||||  Journal:  Intraoperative Prediction of Long-Term Remission in Acromegaly. (Pubmed Central) -  Nov 2, 2022   
    In this Review, we examine the epidemiology, pathogenesis, diagnosis, complications, and treatment of acromegaly, with an emphasis on the importance of tailoring management strategies to each patient to optimise outcomes. Minimum intraoperative GH may predict long-term outcome for acromegaly, which in principle could provide the pituitary neurosurgeon with real-time feedback and inform intraoperative decision making.
  • ||||||||||  Trial completion date, Trial primary completion date:  Modulating the GIP System in Patients With Acromegaly Due to a Pituitary Tumor (clinicaltrials.gov) -  Nov 2, 2022   
    P=N/A,  N=30, Recruiting, 
    Minimum intraoperative GH may predict long-term outcome for acromegaly, which in principle could provide the pituitary neurosurgeon with real-time feedback and inform intraoperative decision making. Trial completion date: Dec 2025 --> Jul 2023 | Trial primary completion date: Dec 2024 --> Jun 2023
  • ||||||||||  Journal:  Filling the gap between the heart and the body in acromegaly: a case-control study. (Pubmed Central) -  Nov 1, 2022   
    Trial completion date: Dec 2025 --> Jul 2023 | Trial primary completion date: Dec 2024 --> Jun 2023 Our study demonstrates higher prevalence of cardiovascular comorbidities in acromegaly patients and the impact of IGF-1 levels and body composition parameters in pathology in some of these comorbidities.
  • ||||||||||  Journal:  Durable Biochemical Response and Safety with Oral Octreotide Capsules in Acromegaly. (Pubmed Central) -  Oct 29, 2022   
    Our study demonstrates higher prevalence of cardiovascular comorbidities in acromegaly patients and the impact of IGF-1 levels and body composition parameters in pathology in some of these comorbidities. Patients with acromegaly maintained long-term biochemical response while receiving OOC, with no new AEs observed with prolonged OOC exposure.
  • ||||||||||  Journal:  Incidence of ossification of the spinal ligaments in acromegaly patients. (Pubmed Central) -  Oct 28, 2022   
    In conclusion, this study suggested a possible association between acromegaly and ossification of the spinal ligaments, although the number of patients was insufficient to draw a conclusion. Acromegaly patients should be tested to confirm, or rule out, spinal ossification, and further studies to clarify the underlying mechanism of spinal ossification in acromegaly patients are warranted.
  • ||||||||||  Journal:  May the SAGIT® instrument be used as a preoperative prognostic tool in patients with acromegaly? (Pubmed Central) -  Oct 27, 2022   
    Acromegaly patients should be tested to confirm, or rule out, spinal ossification, and further studies to clarify the underlying mechanism of spinal ossification in acromegaly patients are warranted. In our retrospective cohort study, the findings suggested that the SAGIT® instrument may be a beneficial preoperative tool to predict the initial remission postoperatively and long-term prognosis of the patients with acromegaly.
  • ||||||||||  Enrollment closed, Trial primary completion date:  Treatment Patterns and Treatment Outcomes for Acromegaly (clinicaltrials.gov) -  Oct 26, 2022   
    P=N/A,  N=520, Active, not recruiting, 
    In our retrospective cohort study, the findings suggested that the SAGIT® instrument may be a beneficial preoperative tool to predict the initial remission postoperatively and long-term prognosis of the patients with acromegaly. Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2022 --> Jul 2023
  • ||||||||||  NN1213 / Novo Nordisk
    Enrollment closed, Trial completion date, Trial primary completion date:  A Prospective Study of Outcome After Therapy for Acromegaly (clinicaltrials.gov) -  Oct 26, 2022   
    P=N/A,  N=250, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2022 --> Jul 2023 Recruiting --> Active, not recruiting | Trial completion date: Jun 2022 --> Jun 2025 | Trial primary completion date: Jun 2022 --> Jun 2025